← Back to headlines
AstraZeneca Explored $400 Billion Merger with Bristol Myers Squibb
AstraZeneca Plc reportedly explored a potential acquisition of Bristol Myers Squibb Co., which would have created a pharmaceutical giant worth an estimated $400 billion. The discussions, if successful, would have resulted in one of the largest mergers in the industry.
2 Aug, 18:30 — 2 Aug, 20:13
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (56/100)4 sources30/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left1
Left (1)
cnbc
Center2
Center (2)
bloombergFT
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 2 regions9/34
US3UK1
Sources
Showing 3 of 4 sources
bloombergHigh1h ago
AstraZeneca Said to Have Explored Bristol Myers Merger
AstraZeneca Plc has explored an acquisition of Bristol Myers Squibb Co., in a megadeal that would create one of the world’s largest drugmakers, according to people familiar with the matter.
By Dinesh Nair, Michelle F. Davis, Ashleigh Furlong and Kelly Gilblom
Read full article →FTVery High3h ago
AstraZeneca holds talks with Bristol Myers Squibb on pharma megadeal
Tie-up would create one of the world’s biggest drugmakers
Read full article →cnbcMostly Factual1h ago
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
Read full article →Coverage Timeline
First report: FT · 2 Aug, 18:30|Full coverage: 4 · 2h|Window: 2h
Left-leaningCenterRight-leaning
